Pharmacotherapy for Allergic Rhinitis

Otolaryngologic Clinics of North America

Volumn 44, Issue 3, 2011, Pages 727-739

  Melvin, Thuy Anh N ^a   Patel, Alpen A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Towson Medical Center   (United States)

Author keywords

Allergic rhinitis; Allergy symptom control; Allergy treatment

Indexed keywords

AZATADINE MALEATE; AZELASTINE; BECLOMETASONE DIPROPIONATE; BROMPHENIRAMINE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CHLORPHENIRAMINE MALEATE; CICLESONIDE; CLEMASTINE; CLEMASTINE FUMARATE; CROMOGLYCATE DISODIUM; DESLORATADINE; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DEXCHLORPHENIRAMINE MALEATE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HYDROXYZINE; IPRATROPIUM BROMIDE; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; MUCOLYTIC AGENT; OLOPATADINE; OXYMETAZOLINE; PROMETHAZINE; RHINOCORT AQ; TRIAMCINOLONE ACETONIDE; TRIPELENNAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ALLERGIC RHINITIS; CLINICAL TRIAL (TOPIC); DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EPISTAXIS; GASTROINTESTINAL SYMPTOM; HUMAN; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; NEPHROLITHIASIS; PRURITUS; RASH; REVIEW; SEDATION; SIDE EFFECT; SNEEZING; UNPLEASANT TASTE; XEROSTOMIA;

ADMINISTRATION, INTRANASAL; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; CHOLINERGIC ANTAGONISTS; CROMOLYN SODIUM; DRUG THERAPY, COMBINATION; EXPECTORANTS; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; NASAL DECONGESTANTS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 79957488781     PISSN: 00306665     EISSN: 15578259     Source Type: Journal    
DOI: 10.1016/j.otc.2011.03.010     Document Type: Review

References (49)

1. Reed S.D., Lee T.A., McCrory D.C. The economic burden of allergic rhinitis: a critical evaluation of the literature. Pharmacoeconomics 2004, 22(6):345-361.
2. Santos C.B., Pratt E.L., Hanks C., et al. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 2006, 97(5):579-586.
3. Blaiss M.S. Allergic rhinitis and impairment issues in school children: a consensus report. Curr Med Res Opin 2004, 20(12):1937-1952.
4. Krouse J.H., Altman K.W. Rhinogenic laryngitis, cough, and the unified airway. Otolaryngol Clin North Am 2010, 43(1):111-121.
5. Mygind N., Andersson M. Topical glucocorticosteroids in rhinitis. Acta Otolaryngol 2006, 126:1022-1029.
6. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J 1973, 4:464-466.
7. Krouse J.H. Allergic rhinitis-current pharmacotherapy. Otolaryngol Clin North Am 2008, 41(2):347-358.
8. Siegel S.C., Katz R.M., Rachelefsky G.S., et al. Multicentric study of beclomethasone dipropionate nasal aerosol in adults with seasonal allergic rhinitis. J Allergy Clin Immunol 1982, 69:345-353.
9. Agertoft L., Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999, 104(5):948-952.
10. Cutler D.L., Banfield C., Affrime M.B., et al. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006, 19(3):146-153.
11. Rinne J., Simola M., Malmberg H., et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol 2002, 109:426-432.
12. Bross-Soriano D., Hanenberg-Milver C., Schimelmitz-Idi J., et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004, 130(2):187-191.
13. Skoner D.P., Rachelefsky G.S., Meltzer E.O., et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000, 105(2):E23.
14. Simons F.E., Simons K.J. Second generation H1-receptor antagonists. Ann Allergy Asthma Immunol 1991, 66:5-17.
15. Canonica G.W., Tarantini F., Compalati E., et al. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007, 62(4):359-366.
16. Bachert C., Bousquet J., Canonica G.W., et al. XPERT Study Group. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004, 114(4):838-844.
17. Shah S., Berger W., Lumry W., et al. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2009, 30(6):628-633.
18. Kaliner M.A., Oppenheimer J., Farrar J.R. Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc 2010, 31(2):112-119.
19. Roland P.S., Ryan M.W., Wall G.M. Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother 2010, 11(9):1559-1567.
20. Roland P.S., Marple B.F., Wall G.M. Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol 2010, 6(2):197-204.
21. Kaliner M.A. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2009, 103(5):373-380.
22. Okubo K., Okuda M., Magara H., et al. Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis. Curr Med Res Opin 2010, 26(7):1657-1665.
23. Benincasa C., Lloyd R.S. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest 1994, 8:225-233.
24. Hampel F.C., Ratner P.H., Van Bavel J., et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010, 105(2):168-173.
25. LaForce C.F., Carr W., Tilles S.A., et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy Asthma Proc 2010, 31(2):132-140.
26. Bernstein J.A. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin 2007, 23(10):2441-2452.
27. Philip G., Malmstrom K., Hampel F.C., et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002, 32:1020-1028.
28. van Adelsberg J., Philip G., Pedinoff A.J., et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003, 58:1268-1276.
29. Chervinsky P., Philip G., Malice M.P., et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004, 92:367-373.
30. Chen S.T., Lu K.H., Sun H.L., et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol 2006, 17:49-54.
31. Patel P., Philip G., Yang W., et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005, 95:551-557.
32. Hung C.H., Hua Y.M., Hsu W.T., et al. Montelukast decreased exhaled nitric oxide in children with perennial allergic rhinitis. Pediatr Int 2007, 49(3):322-327.
33. Wilson A.M., O'Byrne P.M., Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004, 116(5):338-344.
34. Meltzer E.O., NasalCrom Study Group Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. Clin Ther 2002, 24:942-952.
35. Cohan R.H., Bloom F.L., Rhoades R.B., et al. Treatment of perennial allergic rhinitis with cromolyn sodium. Double-blind study on 34 adult patients. J Allergy Clin Immunol 1976, 58:121-128.
36. Wood C.C., Fireman P., Grossman J., et al. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol 1995, 95:1111-1116.
37. Kim K.T., Kerwin E., Landwehr L., et al. Use of 0.06% ipratropium bromide nasal spray in children aged 2 to 5 years with rhinorrhea due to a common cold or allergies. Ann Allergy Asthma Immunol 2005, 94:73-79.
38. Kaiser H.B., Findlay S.R., Georgitis J.W., et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol 1995, 95:1128-1132.
39. Smith S.M., Schroeder K., Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2008, 1. CD001831.
40. Morjaria J.B., Polosa R. Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Rev Respir Med 2009, 3(3):299-308.
41. Casale T.B. Anti-IgE (Omalizumab) therapy in seasonal allergic rhinitis. Am J Respir Crit Care Med 2001, 164(Suppl):S18-S21.
42. Adelroth E., Rak S., Huahtela T., et al. Recombinant humanized mAb-E25, an anti IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 106:253-259.
43. Chervinsky P., Casale T., Townley R., et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003, 91:160-167.
44. Vignola A.M., Humbert M., Bousquet J., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004, 59:709-717.
45. Storms W. Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy. Am J Respir Med 2002, 1(5):361-368.
46. Kamin W., Kopp M.V., Erdnuess F., et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010, 21(1 Pt 2):e160-e165.
47. Stokes J., Casale T. Anti-IgE therapy. Middleton's allergy: principles and practice 2008, 1679-1689. Mosby, St Louis (MO). 7th edition. N.F. Atkinson, B.S. Bochner, W.W. Busse (Eds.).
48. Pinto J.M., Mehta N., DiTineo M., et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010, 48(3):318-324.
49. Peng Z. Vaccines targeting IgE in the treatment of asthma and allergy. Hum Vaccin 2009, 5(5):302-309.